½ÃÀ庸°í¼­
»óǰÄÚµå
1690064

¾Ð·Â ÁÖÀÔ ¹é : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2025-2030³â)

Pressure Infusion Bags - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Ð·Â ÁÖÀÔ ¹é ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 3¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2025-2030³â)ÀÇ CAGRÀº 5.49%¸¦ ³ªÅ¸³»°í, 2030³â¿¡´Â 4¾ï 5,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Pressure Infusion Bags-Market-IMG1

COVID-19ÀÇ À¯ÇàÀº ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. COVID-19ÀÇ ºÀ¼â ±â°£ µ¿¾È º´¿øÀÇ ÀÀ±Þ ºÎ¹® ÀÔ¿øÀÌ Áõ°¡Çϰí COVID-19ÀÇ »ç·Ê ¼ö°¡ ºü¸¥ ¼Óµµ·Î Áõ°¡Ç߱⠶§¹®¿¡ ¾Ð·Â ÁÖÀÔ ¹é ¼ö¿ä°¡ Å©°Ô Áõ°¡Ç߱⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 9¿ù PubMed°¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é ¹Ì±¹¿¡¼­ COVID-19¿Í °ü·ÃµÈ ÀÀ±ÞÁø·á°¡ 0-4¼¼, 5-11¼¼, 12-17¼¼·Î Áõ°¡Çϰí COVID-19°¡ È®ÀÎµÈ È¯ÀÚ ÀÔ¿øÀÌ 2021³â Áß 0-17¼¼·Î Áõ°¡Çß´Ù´Â ¿¬±¸°¡ ÁøÇàµÇ¾ú½À´Ï´Ù.

À§ÀÇ ³í¹®¿¡¼­´Â 2021³â 7¿ù°ú 8¿ù¿¡ ICU¿¡ ÀÔ¿øÇÑ 0-17¼¼ÀÇ COVID-19 ȯÀÚÀÇ ºñÀ²Àº 20%¿Í 18%¿´´Ù°í ÇÕ´Ï´Ù. µû¶ó¼­ ¾Ð·Â ÁÖÀÔ ½ÃÀåÀº COVID-19ÀÇ Å« À¯Çà¿¡ ÀÇÇØ Å« ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹ÍÀº ÇöÀç ħÀüµÇ°í Àֱ⠶§¹®¿¡ Á¶»ç ¿¹Ãø ±â°£ µ¿¾È ¾ÈÁ¤ÀûÀÎ ÃßÀ̰¡ ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϴ ƯÁ¤ ¿äÀÎÀ¸·Î´Â ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ±ä±Þ ¼öÇ÷ »ç·Ê ±ÞÁõ, ±â¼ú Áøº¸, R&D ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. 2022³â 7¿ù È£ÁÖ º¸°Çº¹Áö¿¬±¸¼Ò°¡ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2021³â¿¡´Â È£ÁÖÀÎÀÇ °ÅÀÇ Àý¹Ý(47%, 1,160¸¸¸í)ÀÌ Çϳª ÀÌ»óÀÇ ÀϹÝÀûÀÎ ¸¸¼ºÁúȯ(´ç´¢º´, ¾Ï, Á¤½Å¡¤ÇൿÁúȯ, ¸¸¼º½ÅÀ庴 µî)À» ¾Î°í ÀÖ´Ù°í ÃßÁ¤µÇ¾ú½À´Ï´Ù. µû¶ó¼­ ¸¸¼º Áúȯ ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖÀÔ ¹é ¼ö¿ä´Â ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÕ´Ï´Ù.

°Ô´Ù°¡ JAMA Network°¡ 2022³â 6¿ù¿¡ ½º¿þµ§¿¡¼­ ¿¬±¸ÇØ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é ÀÏ¹Ý Àα¸¿¡¼­ÀÇ ¾ÆÅ×·Ò¼º µ¿¸Æ°æÈ­ÁõÀÇ À¯º´·ü°ú ºÎ´ãÀÌ ¸Å¿ì ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ´ÙÇ÷°ü ¾ÆÅ×·Ò¼º µ¿¸Æ°æÈ­ÁõÀÇ ÃßÁ¤ À¯º´·üÀº 3%¿¡¼­ 42%¿´½À´Ï´Ù. Á×»ó µ¿¸Æ °æÈ­Áõ°ú °°Àº Áúº´ÀÇ Ä¡·á¿¡´Â ¼ö¼ú ÀýÂ÷°¡ Æ÷ÇÔµÇ¾î °¡¾Ð ÁÖÀÔ ¹éÀÇ »ç¿ë·®ÀÌ Áõ°¡ÇÕ´Ï´Ù.

¾Ð·Â ÁÖÀÔ±â´Â ¶ÇÇÑ Ç÷¾×, Ç÷¾× Á¦Á¦, Ç÷¾× È®ÀåÁ¦, Á¤¸ÆÁÖ»ç ¿ë¾×, ħ½ÀÀû Ç÷¾Ð ¸ð´ÏÅ͸µ ÀýÂ÷ÀÇ ±Þ¼Ó ÁÖÀÔ µî ´Ù¾çÇÑ ÀÇ·á ÀýÂ÷¿¡ ÇÊ¿äÇÑ ±¸¼º ¿ä¼Ò°¡ µÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù¿¡ NCBI¿¡ ÀÇÇØ °»½ÅµÈ ³í¹®¿¡ µû¸£¸é, ÀÓ»ó »óȲÀÌ °áÁ¤Áú ÁÖÀÔÀÇ ±Þ¼Ó ÁÖÀÔÀ» Áö½ÃÇÒ ¼ö ÀÖ´Â ±Þ¼º ȯ°æ¿¡¼­ ¾Ð·Â ÁÖÀÔ ¹éÀº ´õ ³ôÀº ÁÖÀÔ ¼Óµµ¸¦ ´Þ¼ºÇϱâ À§ÇØ »ç¿ëµË´Ï´Ù.

µû¶ó¼­, ¸¸¼º Áúȯ Áõ°¡ ¹× ¾Ð·Â ÁÖÀÔ ¹éÀÇ ±â¼úÀû Áøº¸¿Í °°Àº ¾Õ¼­ ¾ð±ÞÇÑ ¸ðµç ¿äÀεéÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ¹Ð¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Ð·Â ÁÖÀÔ ¹é ½ÃÀå µ¿Çâ

Ç÷¾× ¹× ¾à¹° ÁÖÀÔÀº ¿¹Ãø ±â°£ µ¿¾È ¾Ð·Â ÁÖÀÔ ¹é ½ÃÀå¿¡¼­ ¼öÀͼºÀÖ´Â ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç÷¾× ¹× ¾à¹° ÁÖÀÔÀº ¿¹Ãø ±â°£ µ¿¾È ¾Ð·Â ÁÖÀÔ ¹é ½ÃÀå¿¡¼­ ¼öÀͼºÀÖ´Â ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ ¼¼°èÀûÀ¸·Î »ó½ÂÇϰí Àֱ⠶§¹®¿¡ Àú¡¤Á߼ҵ汹¿¡¼­µµ ´Ù¾çÇÑ ¸¸¼ºÁúȯÀÇ Ä¡·á°¡ ¼¼°è º¸°Ç Ä¿¹Â´ÏƼ¿Í Á¤ºÎ¿¡ ÀÇÇØ Á¡Á¡ ¿ì¼±ÀûÀ¸·Î µÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú ¼¼°è Áúº´ ºÎ´ã¿¡ ´ëóÇϱâ À§ÇØ ½Å¼ÓÇÑ ÁÖÀÔ ¼ö¿ä°¡ ÇöÀúÇÏ°Ô ³ô¾ÆÁö°í ¾Ð·Â ÁÖÀÔ ¹éÀÇ »ç¿ë°ú ä¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼ö¾× °ú´Ù´Â ¿ïÇ÷¼º ½ÉºÎÀüÀ̳ª ½ÅºÎÀü µî ´Ù¾çÇÑ Àå±âÀÇ ±â´ÉºÎÀü¿¡ ÀÇÇØ ÀϹÝÀûÀ¸·Î ÀϾ´Â »óÅÂÀÔ´Ï´Ù. Àú»ïÅõ¾ÐÀÌ ÁßÁõÀ̰ųª Àå±â°£ Áö¼ÓµÇ¸é ½ÉÀå ±â´ÉÀÇ º¸»ó º¯È­°¡ ÁøÇ༺ ½ÉºÎÀüÀ¸·Î ¾ÇÈ­µÉ ¼ö ÀÖ½À´Ï´Ù. ±×·¯¹Ç·Î ½ÉºÎÀü ȯÀÚÀÇ Àú¾×·® »óŸ¦ ÇÇÇϱâ À§ÇØ ¾Ð·Â ÁÖÀÔ ¹éÀÌ »ç¿ëµÇ¾î Á¶»çµÈ ½ÃÀå ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Heart and Circulatory Disease Statistics 2023¿¡ µû¸£¸é 2021³âºÎÅÍ 2022³â±îÁö ¿µ±¹ÀÇ NHS º´¿ø¿¡ ½ÉÀ塤¼øÈ¯±â ÁúȯÀ¸·Î ÀÔ¿øÇÑ È¯ÀÚ´Â 936,556¸íÀ̾ú½À´Ï´Ù. ÀÌ´Â 2020-2021³â 807,074¸í¿¡¼­ Áõ°¡Çß½À´Ï´Ù. µû¶ó¼­ º´¿ø¿¡¼­ ½ÉÇ÷°ü Áúȯ ÀÔ¿ø ȯÀÚ Áõ°¡´Â Ç÷¾× ¹× ¾à¹° ÁÖÀÔ ¼ö¿ä¸¦ Áõ°¡½ÃŰ°í ¿¹Ãø ±â°£ µ¿¾È µ¿ÀÏÇÑ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ Áö¿ª¿¡¼­ ¾Ð·Â ÁÖÀÔ ¹éÀÇ °¡¿ë¼ºÀ» ³ôÀ̱â À§ÇÑ Ç÷¾×¡¤¾àÁ¦ ÁÖÀÔ IV ¹éÀÇ Ãâ½Ã, Á¦ÈÞ, ÆÄÆ®³Ê½Ê µî ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ Àü·«Àû Ȱµ¿ Áõ°¡´Â ¿¹Ãø ±â°£¿¡ °ÉÃÄ ½ÃÀå ¼ºÀåÀ» °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù Gufic Biosciences´Â Àεµ¿¡¼­ ¾à¹°Àü´Þ¿ë µà¾ó è¹ö IV ¹éÀ» Ãâ½ÃÇß½À´Ï´Ù. Gufic Biosciences´Â Àεµ¿¡¼­ IV ¹éÀ» »ý»êÇϱâ À§ÇØ ÇÁ¶û½º ÆÄÆ®³Ê¿Í Çù·ÂÇß½À´Ï´Ù.

µû¶ó¼­ ½ÉÇ÷°ü Áúȯ°ú ¾Ï µî ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÁÖ¿ä ±â¾÷ÀÇ Àü·«Àû Ȱµ¿À¸·Î Á¶»ç ´ë»ó ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¿¹Ãø±â°£ Áß ºÏ¹Ì°¡ ¾Ð·Â ÁÖÀÔ ¹é ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇÒ Àü¸Á

ºÏ¹Ì´Â ÁÖ·Î ¸¸¼ºÁúȯÀÇ ³ôÀº À¯º´·ü, ³ôÀº ÇコÄɾî ÁöÃâ, ¸¸¼ºÁúȯÀÇ ¼ö¼úÀû Ä¡·á°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¾Ð·Â ÁÖÀÔ ¹é ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¾Ð·Â ÁÖÀÔ ½Ã½ºÅÛÀÇ ±Þ¼ÓÇÑ Áøº¸´Â ºÏ¹Ì ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ¾Ï Çùȸ°¡ ¹ßÇ¥ÇÑ 2023³â Åë°è¿¡ µû¸£¸é 2023³â ¹Ì±¹¿¡¼­ ¾à 195¸¸ °ÇÀÇ »õ·Î¿î ¾ÏÀÌ Áø´ÜµÇ¾úÀ¸¸ç, ÀÌ´Â 2022³âÀÇ 191¸¸ °Ç°ú ºñ±³ÇßÀ» ¶§ ¾à 2¹è°¡·® Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ¾Ï Ä¡·á´Â ÀÎü¿¡¼­ ¿µ¾çÀ» »©¾Ñ¾Æ ±Ë¾ç, À§Àå ±â´É Àå¾Ö, ¹°¸®Àû Æó»öÀ» ÀÏÀ¸ÄÑ ½Åü¿¡ ¿µÇâÀ» Áֱ⠶§¹®¿¡ ȯÀÚ¿¡°Ô ºñ°æ±¸ ¿µ¾çÀ» °ø±ÞÇÏ´Â ¼ö¿ä°¡ ³ô¾ÆÁý´Ï´Ù. ÀÌ ¶§¹®¿¡ ȯÀÚ¿¡°Ô ¹«±Õ ºñ°æ±¸ ÁÖÀÔÀ» °¡¾Ð ÁÖÀÔÇÏ´Â µ¥ »ç¿ëµÇ´Â °¡¾Ð ÁÖÀÔ ¹é ¼ö¿ä°¡ Áõ°¡ÇÏ°í ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ô´Ù°¡, ±¹³»¿¡¼­ ¼öÇàµÇ´Â Á¤Çü¿Ü°úÀÇ ´ëü¼ú°ú ÈäºÎ ¼ö¼ú°ú °°Àº º¹ÀâÇÑ ¼ö¼úÀº ´ëºÎºÐÀÇ Á¤¸Æ ÁÖ»çÁ¦°¡ ¾Ð·Â ÁÖÀÔ ¹éÀ» ÅëÇØ Åõ¿©µÇ±â ¶§¹®¿¡ ¾Ð·Â ÁÖÀÔ ¹é ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ij³ª´Ù °Ç°­Á¤º¸¿¬±¸¼Ò°¡ 2022³â 12¿ù¿¡ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é, ij³ª´Ù¿¡¼­´Â 2021³âºÎÅÍ 2022³â¿¡ °ÉÃÄ ¾à 700°ÇÀÇ ¿Ü·¡È¯ÀÚ¿¡ ÀÇÇÑ °í°üÀý ġȯ¼ú°ú ¹«¸­ °üÀý ġȯ¼úÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù. ÀÌ¿Í °°ÀÌ Ä¡È¯¼úÀÇ °Ç¼ö°¡ ¸¹±â ¶§¹®¿¡ ¿¹Ãø±â°£ Áß ½ÃÀå ¼ºÀåÀÌ ±â´ëµË´Ï´Ù.

°Ô´Ù°¡ 2021³â Àü¹Ì ¾ÈÀüÀ§¿øÈ¸ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 2021³â¿¡ 320¸¸¸íÀÌ ½ºÆ÷Ã÷³ª ·¹Å©¸®¿¡ÀÌ¼Ç µµ±¸¿¡ ÀÇÇÑ ºÎ»óÀ¸·Î ±¸±ÞºÎ¿¡¼­ Ä¡·á¸¦ ¹Þ¾Ò½À´Ï´Ù. ºÎ»ó°ú °¡Àå ÀÚÁÖ °ü·ÃµÈ Ȱµ¿Àº ¿îµ¿, »çÀÌŬ¸µ, ³ó±¸ÀÔ´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ À¯ÇüÀÇ È°µ¿°ú °ü·ÃµÈ ºÎ»ó ¼ö Áõ°¡´Â ¾Ð·Â ÁÖÀÔ ¹éÀÇ Ã¤¿ëÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ Àμö, Á¦ÈÞ, ±âŸ ÀÌ´Ï¼ÅÆ¼ºê µî ´Ù¾çÇÑ ÁÖ¿ä Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºêÀÇ Ã¤Åÿ¡ ±â¾÷ÀÌ ÁÖ·ÂÇÏ°Ô µÇ¸é¼­ ½ÃÀå¿¡¼­ÀÇ ¼ö¾×¹éÀÇ ¼ö°¡ Áõ°¡ÇÏ¿© ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 1¿ù ICU Medical Inc.´Â Smiths Group PLC¿¡¼­ Smiths Medical Àμö¸¦ ¿Ï·áÇß½À´Ï´Ù. Smiths MedicalÀÇ »ç¾÷¿¡´Â ÁÖ»ç±â ¹× ¿Ü·¡¿ë ÁÖÀÔ ÀåÄ¡(¾Ð·Â ÁÖÀÔ ¹é Æ÷ÇÔ), ¹ö½ºÅ§·¯ Á¢±Ù, »ýü Äɾî Á¦Ç° µîÀÌ Æ÷ÇԵ˴ϴÙ.

µû¶ó¼­ ¸¸¼ºÁúȯ Áõ°¡¿Í ¼ö¼úÀÇ Çʿ伺 µî ¾Õ¼­ ¾ð±ÞÇÑ ¸ðµç ¿äÀεéÀÌ ÁÖ¿ä ±â¾÷ÀÇ Àü·«Àû Àμö¿Í ÇÔ²² ºÏ¹Ì ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Ð·Â ÁÖÀÔ ¹é »ê¾÷ °³¿ä

¾Ð·Â ÁÖÀÔ ¹é ½ÃÀåÀº Àû´çÇÏ°Ô ´ÜÆíÈ­µÇ°í, ¼Ò¼öÀÇ ¼±µµ ±â¾÷À¸·Î ±¸¼ºµË´Ï´Ù. Eakin Healthcare Group(Armstrong Medical Inc.), Merit Medical System, ICU Medical Inc., Tapmedic LLC, SunMed µîÀÇ ±â¾÷ÀÌ ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

±âŸ ÇýÅà :

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® ¼­Æ÷Æ®

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º Áúȯ Áõ°¡¿Í ±ä±Þ ¼öÇ÷ »ç·ÊÀÇ ±ÞÁõ
    • ±â¼úÀÇ Áøº¸¿Í ¿¬±¸°³¹ß ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚ/¼ÒºñÀÚÀÇ Çù»ó·Â
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°èÀÇ °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Á¦Ç° À¯Çüº°
    • Àç»ç¿ë °¡´É
    • ÀÏȸ¿ë
  • Àç·áº°
    • ³ªÀÏ·Ð
    • Æú¸®¿ì·¹Åº
    • ±âŸ Àç·á
  • ¿ëµµº°
    • Ç÷¾× ¹× ¾à¹° ÁÖÀÔ
    • ħ½ÀÀû Ç÷¾Ð ¸ð´ÏÅ͸µ ÀýÂ÷
  • ÃÖÁ¾ »ç¿ëÀÚº°
    • º´¿ø ¹× Áø·á¼Ò
    • ¿Ü·¡È¯Àڽü³
    • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ
  • Áö¿ªº°
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¼¼°è ±âŸ Áö¿ª

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Eakin Healthcare Group(Armstrong Medical Inc.)
    • Ecomed
    • Merit Medical Systems
    • Sarstedt AG & Co. KG
    • ICU Medical Inc.
    • SunMed
    • Tapmedic LLC
    • VBM Medizintechnik GmbH
    • Spengler SAS
    • Fairmont Medical
    • Biegler GmbH

Á¦7Àå ½ÃÀå ±âȸ¿Í ¾ÕÀ¸·ÎÀÇ µ¿Çâ

KTH 25.04.09

The Pressure Infusion Bags Market size is estimated at USD 0.35 billion in 2025, and is expected to reach USD 0.45 billion by 2030, at a CAGR of 5.49% during the forecast period (2025-2030).

Pressure Infusion Bags - Market - IMG1

The COVID-19 pandemic had a significant impact on the market since the demand for pressure infusion bags increased considerably during the COVID-19 lockdown with the number of COVID-19 cases increasing at a faster rate with increased hospital emergency department admissions. For instance, according to an article published by PubMed in September 2021, a study was conducted in the United States which showed that COVID-19-related emergency visits increased for persons aged 0-4, 5-11, and 12-17 years, and hospital admissions of patients with confirmed COVID-19 increased for persons aged 0-17 years during 2021.

The abovementioned article also stated that the proportion of COVID-19 patients aged 0-17 years who were admitted to an ICU ranged from 20% and 18% during July and August 2021. Thus, the pressure infusion market was significantly impacted by the COVID-19 pandemic. However, as the pandemic has subsided currently, the studied market is expected to have stable during the forecast period of the study.

Certain factors that are driving the market growth include the rising prevalence of chronic diseases and surge in emergency transfusion cases and technological advancements, and increasing R&D initiatives. According to the data published by the Australian Institute of Health and Welfare in July 2022, it is estimated that almost half (47%, or 11.6 million) of Australians have one or more common chronic health conditions (including diabetes, cancer, mental and behavioral conditions, and chronic kidney disease) in 2021. Therefore, as the number of chronic disease patients increases, the demand for infusion bags will increase over the projected period.

Moreover, according to an article published by JAMA Network in June 2022, a study was conducted in Sweden which showed that the prevalence and burden of atherosclerosis in the general population have been very high, and the estimated prevalence of poly-vascular atherosclerosis ranged from 3% to 42%. The treatment of diseases like atherosclerosis includes surgical procedures, which will lead to more usage of pressure infusion bags.

The pressure infuser has also become a necessary component of various medical procedures such as rapid infusion of blood, blood products, blood expanders, IV solutions, and invasive pressure monitoring procedures. For instance, according to an article updated by NCBI in August 2022, in an acute setting, where the clinical situation might indicate a rapid infusion of crystalloid fluids, pressure infusion bags are used to achieve a higher infusion rate.

Thus, all aforementioned factors, such as the increasing number of chronic diseases and the technological advancement in pressure infusion bags, are expected to boost the market over the forecast period. However, the lack of skilled professionals is expected to impede the growth of the market.

Pressure Infusion Bags Market Trends

Blood and Drug Infusion is Expected to Show Lucrative Growth in the Pressure Infusion Bags Market Over the Forecast Period

Blood and drug infusions are carried out whenever any surgical procedure takes place that involves the loss of blood or the need for drug injection through infusion bags. As the prevalence of chronic diseases is rising worldwide, the treatment of various chronic diseases has been increasingly prioritized by the global health community or governments, even in low- and middle-income countries. As a result, the demand for rapid fluid transfusion has risen significantly in order to address the global disease burden, thus leading to a rise in the utilization and adoption of pressure infusion bags.

Hypovolemia is a condition that is commonly caused by dysfunction of various organs, such as congestive heart failure or kidney failure. If the hypovolemia is severe or persists over a long period of time, the compensatory changes in cardiac function may deteriorate into progressive cardiac failure. Hence, to avoid hypovolemia conditions in heart failure patients, pressure infusion bags are used, which is expected to increase the demand for the market studied.

According to the Heart and Circulatory Disease Statistics 2023, 936,556 patients were admitted to NHS hospitals in England for heart and circulatory diseases during 2021-2022. This was an increase from 807,074 patients in 2020-2021. Hence, the increase in cardiovascular disease admissions in hospitals is expected to increase the demand for blood and drug infusions, thereby contributing to the segment's growth over the forecast period.

Additionally, the increase in strategic activities by key players like blood and drug infusion IV bag launches, collaboration, and partnerships to increase the availability of pressure infusion bags across various regions are expected to bolster market growth over the forecast period. For instance, in June 2022, Gufic Biosciences launched dual-chamber IV bags for drug delivery in India. Gufic Biosciences collaborated with its French counterpart to manufacture the IV bag in India.

Hence, with the growing prevalence of chronic diseases such as cardiovascular diseases and cancer and strategic activities by the key players, the studied segment is expected to witness growth over the forecast period.

North America is Expected to Hold a Significant Share in the Pressure Infusion Bags Market Over the Forecast Period

North America is expected to hold a significant share of the pressure infusion bags market, primarily due to the high prevalence of chronic diseases, high healthcare expenditures, and the increase in surgical treatments for chronic diseases. In addition, the rapid advancements in pressure infusion systems are also expected to fuel market growth in the North American region.

According to the 2023 statistics published by the American Cancer Society, about 1.95 million new cancer cases are expected to be diagnosed in the United States in 2023, as compared to 1.91 million cases in 2022. Cancer treatment deprives the human body of nutrition and affects the body by causing ulcers, gastrointestinal dysfunction, and physical blockages, which increases the demand for delivering parenteral nutrition to patients. This is expected to fuel demand for pressure infusion bags, which are used to pressurize sterile parenteral fluids to patients, boosting market expansion.

Additionally, complex procedures, such as orthopedic replacements or thoracic surgery, performed in the country are expected to increase the demand for pressure infusion bags since intravenous medications are mostly given through pressure infusion bags. For instance, according to the data published by the Canadian Institute for Health Information in December 2022, about 700 outpatient hip and knee replacements were performed in Canada during 2021-2022. Thus, a high number of replacement procedures is expected to fuel market growth over the forecast period.

Furthermore, according to the data from the National Safety Council in 2021, an estimated 3.2 million people were treated in emergency departments for injuries involving sports and recreational equipment in the United States in 2021. The activities most frequently associated with injuries are exercise, cycling, and basketball. Therefore, the rise in the number of injuries associated with these types of activities is also expected to increase the adoption of pressure infusion bags.

Additionally, the increasing focus of the companies on adopting various key strategic initiatives such as acquisitions, partnerships, and other initiatives is expected to increase the number of infusion bags in the market, thereby propelling market growth. For instance, in January 2022, ICU Medical Inc. completed its acquisition of Smiths Medical from Smiths Group PLC. The Smiths Medical business includes syringes and ambulatory infusion devices (including pressure infusion bags), vascular access, and vital care products.

Hence, all the aforementioned factors, such as the increasing number of chronic diseases and their requirement for surgeries, coupled with strategic acquisitions by the key players, are expected to boost the growth of the market in the North America Region.

Pressure Infusion Bags Industry Overview

The pressure infusion bags market is moderately fragmented and consists of a few major players. Companies like Eakin Healthcare Group (Armstrong Medical Inc.), Merit Medical System, ICU Medical Inc., Tapmedic LLC, and SunMed hold a substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Chronic Diseases and Surge in Emergency Transfusion Cases
    • 4.2.2 Technological Advancements and Increasing R&D Initiatives
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Professionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Product Type
    • 5.1.1 Reusable
    • 5.1.2 Disposable
  • 5.2 By Material
    • 5.2.1 Nylon
    • 5.2.2 Polyurethane
    • 5.2.3 Other Materials
  • 5.3 By Application
    • 5.3.1 Blood and Drug Infusion
    • 5.3.2 Invasive Pressure Monitoring Procedures
  • 5.4 By End Users
    • 5.4.1 Hospitals and Clinics
    • 5.4.2 Outpatient Facilities
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Eakin Healthcare Group (Armstrong Medical Inc.)
    • 6.1.2 Ecomed
    • 6.1.3 Merit Medical Systems
    • 6.1.4 Sarstedt AG & Co. KG
    • 6.1.5 ICU Medical Inc.
    • 6.1.6 SunMed
    • 6.1.7 Tapmedic LLC
    • 6.1.8 VBM Medizintechnik GmbH
    • 6.1.9 Spengler SAS
    • 6.1.10 Fairmont Medical
    • 6.1.11 Biegler GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦